8-K: Exicure Reports Q3 2025 Results, Faces Going Concern Warning

Exicure, Inc. announced its third-quarter 2025 financial results, reporting a significant net loss increase and a going concern warning due to insufficient cash to fund operations.

Summary

• Cash and cash equivalents were $4.4 million as of September 30, 2025, a decrease from $12.5 million as of December 31, 2024.
• Research and development (R&D) expenses were $0.9 million for the quarter ended September 30, 2025, up from $0 for the same period in 2024, primarily due to the acquisition of GPCR Therapeutics USA Inc. (GPCR USA).
• General and administrative (G&A) expenses were $1.5 million for the quarter ended September 30, 2025, an increase from $1.4 million for the same period in 2024, mostly due to additional expenses from the GPCR USA acquisition.
• The Company reported a net loss of $2.4 million for the quarter ended September 30, 2025, compared to a net loss of $1.1 million for the same period in 2024, mainly driven by increased operating expenses from GPCR USA.
• Management believes that existing cash and cash equivalents are not sufficient to continue to fund operations, and the ability to further cut costs and extend the operating runway is limited.
• Substantial additional financing is needed in the short term to pay expenses, fund the ongoing exploration of strategic alternatives, and pursue any identified alternatives.

Sentiment

Score: 2

Explanation: The filing presents a highly negative financial picture with a significant cash burn, increased net loss, and an explicit 'going concern' warning. While the acquisition of GPCR USA and its pipeline offer a potential future, the immediate financial instability and the urgent need for capital overshadow any positive developments.

Positives

• Acquired GPCR Therapeutics USA Inc. in January, bringing a clinical-stage biotechnology company focused on hematologic diseases into the portfolio.
• The lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.
• Recognized a gain of $155,000 from satisfying its self-insured retainer with the insurer during the third quarter of 2025.

Negatives

• Cash and cash equivalents significantly decreased to $4.4 million as of September 30, 2025, from $12.5 million as of December 31, 2024.
• Net loss increased to $2.4 million for the quarter ended September 30, 2025, from $1.1 million for the same period in 2024.
• Management explicitly stated that existing cash and cash equivalents are not sufficient to continue to fund operations, indicating a 'going concern' issue.
• The Company's ability to further cut costs and extend its operating runway is limited.
• Recognized a loss of $246,000 related to the change in the fair value of its contingent liability.
• Incurred a $4,000 loss from GPCR USA's sale of fixed assets.

Risks

• Existing cash and cash equivalents are not sufficient to continue to fund operations.
• The ability to further cut costs and extend the Company's operating runway is limited.
• Substantial additional financing is needed in the short term to pay expenses, fund the ongoing exploration of strategic alternatives, and pursue any alternatives that may be identified.
• There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.
• Risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025.

Future Outlook

The Company is actively exploring strategic alternatives to maximize stockholder value. Substantial additional financing is needed in the short term to fund operations, explore strategic options, and pursue any identified alternatives. There is no assurance that such financing will be available or on acceptable terms. The Company's current business plans and objectives include the pursuit of strategic alternatives, the timing of equity investment closing, potential additional equity investment, and the Nasdaq Hearings Panel process and potential results.

Management Comments

• Management believes that the Company's existing cash and cash equivalents is not sufficient to continue to fund operations.
• The Company has already engaged in significant cost reductions, and our ability to further cut costs and extend the Company's operating runway is limited.
• Substantial additional financing is needed in the short term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified.
• There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.

Industry Context

Exicure, a biotechnology company, is navigating a challenging financial period, common for early-stage biotech firms post-restructuring and acquisition. The focus on hematologic diseases and stem cell mobilization aligns with growing interest in cell and gene therapies, a high-potential but capital-intensive area of the biotech industry. The need for significant additional financing and the 'going concern' warning highlight the inherent risks and funding pressures faced by companies in this sector, especially those exploring strategic alternatives after suspending prior clinical activities.

Comparison to Industry Standards

• The 'going concern' warning indicates a significant deviation from the financial stability typically expected of publicly traded companies, even within the high-risk biotechnology sector.
• The substantial cash burn, with cash and cash equivalents dropping from $12.5 million to $4.4 million in nine months, is a concern, especially when compared to industry peers that often maintain longer cash runways to fund extensive R&D pipelines.
• The increase in R&D expenses to $0.9 million from $0, following the acquisition of GPCR USA, suggests a renewed but nascent investment in pipeline development, which is a positive step but still modest compared to established clinical-stage biotech companies with multiple active trials.
• The net loss of $2.4 million for the quarter, while not uncommon for a development-stage biotech, is exacerbated by the limited cash position and the explicit statement of insufficient funds for ongoing operations, placing it in a more precarious position than many industry benchmarks.

Stakeholder Impact

• Shareholders: Face significant dilution risk if new capital is raised, potential for further share price decline due to the going concern warning and financial instability. Uncertainty regarding the outcome of strategic alternatives.
• Employees: Potential for further restructuring or layoffs if financing is not secured or strategic alternatives are not successful.
• Creditors: Increased risk of default given the 'going concern' warning and insufficient cash.
• Customers/Partners: Potential disruption to ongoing research and development activities if funding issues persist.

Next Steps

• Continue exploring strategic alternatives to maximize stockholder value.
• Seek substantial additional financing in the short term to fund operations and strategic initiatives.
• Pursue any identified strategic alternatives.
• Address the Nasdaq Hearings Panel process.

Key Dates

Recommendation

The company explicitly states it has insufficient cash to fund operations and faces a 'going concern' warning, indicating severe financial distress and a high risk of insolvency or significant dilution. While there's an acquired pipeline, the immediate liquidity crisis and the uncertainty of securing additional financing on acceptable terms make the stock a 'strong sell'. The increased net loss and substantial cash burn further underscore the precarious financial position, making it an extremely high-risk investment with significant downside potential.

Keywords

Exicure, XCUR, Q3 2025, Financial Results, Biotechnology, GPCR Therapeutics, Hematologic Diseases, Stem Cell Mobilization, Multiple Myeloma, Sickle Cell Disease, Cell and Gene Therapy, Going Concern, Capital Raise, Strategic Alternatives, R&D Expense, Net Loss